Published in N Engl J Med on January 14, 1993
Error in chemotherapy dosages. N Engl J Med (1993) 0.75
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med (1992) 3.11
Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol (1989) 6.86
U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol (2002) 4.92
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol (2001) 4.45
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet (2001) 4.16
UK guidelines for the management of cutaneous melanoma. Br J Plast Surg (2002) 3.51
Infectious complications of subcutaneous interleukin-2 and interferon-alpha. Lancet (1992) 2.65
Natural history of stage IV epithelial ovarian cancer. J Clin Oncol (1999) 2.52
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol (2012) 2.23
Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol (2010) 2.22
Management of metastatic melanoma during pregnancy. BMJ (1998) 2.10
Ovarian cancers related to minimal access surgery. Br J Obstet Gynaecol (1995) 2.02
Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol (1996) 1.78
Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol (2001) 1.55
Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck. Ann Oncol (1997) 1.53
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer (1995) 1.52
Indolent cutaneous prodrome of fatal HTLV-I infection. Lancet (1990) 1.48
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res (1993) 1.42
Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone. Cancer Chemother Pharmacol (1988) 1.38
Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol (2007) 1.29
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer (2013) 1.24
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer (2000) 1.18
Revised UK guidelines for the management of cutaneous melanoma 2010. J Plast Reconstr Aesthet Surg (2010) 1.16
Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol (1997) 1.15
Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol (1995) 1.15
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer (2000) 1.13
Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem (1999) 1.12
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer (1999) 1.08
Mucinous ovarian cancer. Int J Gynecol Cancer (2007) 1.07
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer (2007) 1.05
A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer (1996) 1.03
A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer (2004) 1.01
Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol (1999) 1.01
Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol (2005) 1.01
Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol (1995) 1.00
Sex, pregnancy, hormones, and melanoma. BMJ (1993) 0.96
Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin. Postgrad Med J (1994) 0.96
Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. Clin Oncol (R Coll Radiol) (1998) 0.95
The significance of paracardiac lymph node enlargement in ovarian cancer. Clin Radiol (1997) 0.94
Propylene glycol pharmacokinetics and effects after intravenous infusion in humans. Ther Drug Monit (1987) 0.94
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer (1998) 0.94
Disturbance of blood-brain barrier after bone-marrow transplantation. Lancet (1985) 0.93
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer (1990) 0.92
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol (1987) 0.91
Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century. Clin Oncol (R Coll Radiol) (2003) 0.90
Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol (1994) 0.90
A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology. Br J Cancer (2013) 0.90
Identification of the paraproteins and clinical significance of more than one paraprotein and clinical significance of more than one paraprotein in serum of 56 patients. J Clin Pathol (1979) 0.89
The natural history and management of Merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital. Clin Oncol (R Coll Radiol) (1997) 0.88
Significance of tumour calcification in ovarian carcinoma. Br J Radiol (2009) 0.88
The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer (2001) 0.88
Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer (1997) 0.88
Caelyx: phase II studies in ovarian cancer. Eur J Cancer (2001) 0.87
Chinese restaurant syndrome: fact or fiction? Lancet (1980) 0.87
A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency. J Clin Endocrinol Metab (2006) 0.87
Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer. Semin Oncol (1997) 0.87
Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. Neurotoxicology (2007) 0.86
Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer (2004) 0.85
High-dose chemotherapy and autologous bone marrow transplantation for myeloma. Eur J Haematol Suppl (1989) 0.85
Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Clin Oncol (R Coll Radiol) (2009) 0.85
Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer (2000) 0.85
Delayed haemolytic transfusion reaction caused by anti-M antibody in a patient receiving interleukin-2 and interferon for metastatic renal cell cancer. Clin Lab Haematol (1999) 0.85
Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther (1999) 0.85
Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol (1993) 0.85
Monoclonal antibodies recognizing epitopes carried on both glycolipids and glycoproteins of the human milk fat globule membrane. Biochem J (1985) 0.85
Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol Oncol (2011) 0.84
The role of human endogenous retroviruses in melanoma. Br J Dermatol (2009) 0.84
Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol (2000) 0.84
Therapy naivete in the era of potent antiretroviral therapy. J Clin Epidemiol (2001) 0.84
Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer. Semin Oncol (1999) 0.83
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer (2006) 0.83
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Ann Oncol (2009) 0.83
High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index. Br J Cancer (1996) 0.83
Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck. Br J Cancer (1992) 0.83
Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer (1994) 0.83
Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan. Cancer Chemother Pharmacol (1990) 0.83
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer (2010) 0.82
cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro. J Inorg Biochem (2001) 0.82
New approaches to the systemic treatment of melanoma. Cancer Treat Rev (1999) 0.81
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer (1994) 0.81
Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma. Ann Oncol (2003) 0.81
Tumour necrosis factor, cholestatic jaundice, and chronic liver disease. Gut (1990) 0.80
Infectious complications of interleukin 2 therapy. Cytokine (1990) 0.80
Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. Eur J Cancer (2000) 0.80
Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma. Br J Dermatol (2007) 0.80
Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. Br J Cancer (2003) 0.80
Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid. Cancer Chemother Pharmacol (1991) 0.80
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer (2011) 0.80
Gastrostomy tubes in patients with recurrent gynaecological cancer and intestinal obstruction. Br J Obstet Gynaecol (1999) 0.80
Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer. J Med Chem (1997) 0.79
IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL). Clin Exp Immunol (1996) 0.79
A new standard of care for treatment of ovarian cancer. Eur J Cancer (2000) 0.79
A monoclonal antibody which differentiates between bound and free human secretory component. Eur J Immunol (1984) 0.79
In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma. Br J Haematol (1989) 0.79